YM BioSciences seeks $70m from public offering
This article was originally published in Scrip
Canadian drug development company YM BioSciences is looking to raise $70 million in a public offering announced on 23 February, having priced 35 million common shares at $2 a share. The offering is expected to close on or around 29 February 2012.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.